In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa

Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii

(2014) Irene Galani et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease

(2013) Gauri G. Rao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistance Development of Cystic Fibrosis Respiratory Pathogens When Exposed to Fosfomycin and Tobramycin Alone and in Combination under Aerobic and Anaerobic Conditions

(2013) Gerard McCaughey et al.   PLoS One

Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy

(2013) Robbert Crusio et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula

(2011) Phillip J. Bergen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients

(2011) S. M. Garonzik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin: new lessons on an old antibiotic

(2011) D. Yahav et al.   CLINICAL MICROBIOLOGY AND INFECTION

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates

(2011) G. Samonis et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens

(2011) D. E. Karageorgopoulos et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Multidrug-resistant Gram-negative infections: the use of colistin

(2010) Argyris S Michalopoulos et al.   Expert Review of Anti-Infective Therapy

Multidrug-Resistant Gram-Negative Infections

(2009) Helen Giamarellou et al.   DRUGS

Imipenem Resistance in Pseudomonas aeruginosa Emergence, Epidemiology, and Impact on Clinical and Economic Outcomes

(2009) Ebbing Lautenbach et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections

(2009) Nikos Roussos et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies

(2008) N. Petrosillo et al.   CLINICAL MICROBIOLOGY AND INFECTION

Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled study

(2008) Nikolaos Markou et al.   CLINICAL THERAPEUTICS

Re-emergence of colistin in today's world of multidrug-resistant organisms: personal perspectives

(2008) Matthew E Falagas et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS